TargetMol

Miransertib

Product Code:
 
TAR-T3467
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3467-1mg1mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3467-5mg5mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3467-1mL1 mL * 10 mM (in DMSO)£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3467-10mg10mg£209.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3467-25mg25mg£362.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3467-50mg50mg£550.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3467-100mg100mg£838.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3467-500mg500mg£1,589.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
ARQ-092 is an orally bioavailable, selective, and potent allosteric Akt inhibitor.
CAS:
1313881-70-7
Formula:
C27H24N6
Molecular Weight:
432.531
Pathway:
PI3K/Akt/mTOR signaling; Microbiology/Virology; Cytoskeletal Signaling
Purity:
0.98
SMILES:
Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1
Target:
Akt; Parasite

References

Han P, Hou Y, Zhao Y, et al. Low-dose decitabine modulates T cell homeostasisand restores immune tolerance in immune thrombocytopenia. Blood. 2021 Yu Y, et al. PLoS One. 2015, 10(10):e20140479. Han P, Hou Y, Zhao Y, et al. Low-dose decitabine modulates T cell homeostasisand restores immune tolerance in immune thrombocytopenia[J]. Blood. 2021 Lindhurst MJ, et al. Sci Rep. 2015, 5:17162. Kim K, et al. Haematologica. 2017, 102(2):246-259.